Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world.
BACKGROUND
Increasing attention is being paid to the affordability of medicines in low- and middle-income countries (LICs and MICs) where medicines are often highly priced in relation to income levels. The impoverishing effect of medicine purchases can be estimated by determining pre- and postpayment incomes, which are then compared to a poverty line. Here we estimate the impoverishing effects of four medicines in 16 LICs and MICs using the impoverishment method as a metric of affordability.


RESULTS
Affordability was assessed in terms of the proportion of the population being pushed below US$1.25 or US$2 per day poverty levels because of the purchase of medicines. The prices of salbutamol 100 mcg/dose inhaler, glibenclamide 5 mg cap/tab, atenolol 50 mg cap/tab, and amoxicillin 250 mg cap/tab were obtained from facility-based surveys undertaken using a standard measurement methodology. The World Bank's World Development Indicators provided household expenditure data and information on income distributions. In the countries studied, purchasing these medicines would impoverish large portions of the population (up to 86%). Originator brand products were less affordable than the lowest-priced generic equivalents. In the Philippines, for example, originator brand atenolol would push an additional 22% of the population below US$1.25 per day, whereas for the lowest priced generic equivalent this demographic shift is 7%. Given related prevalence figures, substantial numbers of people are affected by the unaffordability of medicines.


CONCLUSIONS
Comparing medicine prices to available income in LICs and MICs shows that medicine purchases by individuals in those countries could lead to the impoverishment of large numbers of people. Action is needed to improve medicine affordability, such as promoting the use of quality assured, low-priced generics, and establishing health insurance systems. Please see later in the article for the Editors' Summary.
Niëns
Laurens M
LM
Institute for Medical Technology Assessment and Institute for Health Policy & Management, Erasmus University Rotterdam, The Netherlands. niens@bmg.eur.nl
Cameron
Alexandra
A
Van de Poel
Ellen
E
Ewen
Margaret
M
Brouwer
Werner B F
WB
Laing
Richard
R
D003431:Cross-Cultural Comparison; D003906:Developing Countries / Q000191:economics*; D018954:Drugs, Essential / Q000191:economics*; D005252:Fees, Pharmaceutical; D006297:Health Services Accessibility / Q000191:economics*; D006801:Humans; D011203:Poverty / Q000191:economics* / Q000208:ethnology; D014480:United Nations / Q000191:economics; D014944:World Health Organization / Q000191:economics
D018954:Drugs, Essential
Bull World Health Organ. 2012 Mar 1;90(3):219-27
22461717
HIV AIDS Policy Law Rev. 2007 May;12(1):28-9
17715529
Bull World Health Organ. 2009 Jul;87(7):520-8
19649366
Lancet. 2009 Jan 17;373(9659):240-9
19042012
Health Econ. 2008 Dec;17(12):1393-412
18246595
Lancet. 2009 Mar 28;373(9669):1081; author reply 1081-2
19329001
J Health Econ. 2006 Jul;25(4):650-73
16806543
AIDS. 2007 Jul;21 Suppl 4:S21-9
17620749
Lancet. 2006 Oct 14;368(9544):1357-64
17046468